John Mascarenhas, MD, discusses the phase III PACIFICA study on the dual JAK2 and FLT3 inhibitor pacritinib in patients with myelofibrosis. The results were presented at the 2022 American Society of Hematology Annual Meeting.
John Mascarenhas, MD, on the Phase III PACIFICA Trial of Pacritinib in Myelofibrosis
By Leah Sherwood, John Mascarenhas, MD - Last Updated: April 12, 2023Post Tags:MPN ASH 22
Related Posts
Robert Daly, MD discusses how symptom monitoring after discharge can reduce readmissions in cancer care.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
TAG shows promise for BPDCN patients under 50, reducing toxicity and enabling safer transplants.
Tuspetinib plus standard of care venetoclax and azacitidine in newly-diagnosed AML showed promising safety and efficacy.
Pirtobrutinib, CAR T, and bispecifics are reshaping CLL care for high-risk, relapsed patients with limited options.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.